Related Experiment Video
Updated: Jun 13, 2025
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
Published on: August 18, 2015
Drug therapies for stroke prevention
Nimisha Shaji1, Robert F Storey2, William A E Parker3
1Final Year Medical Student.
Insights
Stroke prevention involves managing risk factors like atrial fibrillation with oral anticoagulation and atherosclerotic cardiovascular diseases with antiplatelet therapy. Comprehensive assessment and treatment are key to reducing stroke incidence and its impact.
Area of Science:
- Neurology
- Cardiology
- Preventive Medicine
Background:
- Stroke is a leading cause of death, disability, and economic burden.
- Understanding different stroke types (thrombotic, embolic, hemorrhagic) is crucial for effective prevention.
- Key risk factors include atrial fibrillation, atherosclerotic cardiovascular diseases, hypertension, dyslipidemia, and diabetes.
Purpose of the Study:
- To outline comprehensive strategies for stroke prevention.
- To emphasize the importance of risk factor modification.
Main Methods:
- Review of current guidelines and evidence for stroke prevention therapies.
- Discussion of pharmacological interventions including oral anticoagulation and antiplatelet therapy.
- Highlighting the role of blood pressure, lipid, and glycemic control.
Main Results:
- Oral anticoagulation is recommended for patients with atrial fibrillation/flutter.
- Antiplatelet therapy is indicated for patients with established atherosclerotic cardiovascular diseases.
- Intensified antiplatelet therapy or combined therapy can further reduce ischemic stroke risk but increases bleeding risk.
- Blood pressure, lipid, and glycemic control are essential.
- Inflammation is an emerging target for stroke prevention.
Conclusions:
- Comprehensive assessment and pharmacological management of risk factors are central to stroke prevention.
- Tailoring therapies based on stroke type and patient risk factors is critical.
- Ongoing research into novel targets like inflammation may offer future prevention strategies.
Abstract:
Stroke is a major cause of mortality, morbidity and economic burden. Strokes can be thrombotic, embolic or haemorrhagic. The key risk factor for cardioembolic stroke is atrial fibrillation or flutter, and oral anticoagulation (OAC) is recommended in all but the lowest-risk patients with evidence of these arrhythmias. Risk factors for thrombotic stroke overlap strongly with those for other atherosclerotic cardiovascular diseases (ASCVDs). Antiplatelet therapy (APT) should be considered in patients with established ASCVD to reduce risk of cardiovascular events, including stroke. Intensification from single to dual APT or a combination of APT with low-dose OAC can reduce ischaemic stroke risk further, but increases bleeding risk. Blood pressure and lipid profile should be controlled appropriately to guideline targets. In patients with diabetes, good glycaemic control can reduce stroke risk. Inflammation is another emerging target for stroke prevention. Overall, comprehensive assessment and pharmacological modification of risk factors are central to stroke prevention.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:28Drug Therapy
Antianxiety Medications
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System